These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19565241

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
    Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T.
    Georgian Med News; 2007 Jun; (147):52-5. PubMed ID: 17660602
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
    Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS.
    Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M, Marusawa H, Yamada R, Nasu A, Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T, Matsuda F.
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [Abstract] [Full Text] [Related]

  • 7. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of chronic hepatitis C in patients without previous treatment].
    Dehesa Violante M.
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S42-4. PubMed ID: 12712852
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients.
    Uesawa Y, Motege E, Dai Y, Ishii K, Mohri K.
    Pharmazie; 2010 Feb; 65(2):114-6. PubMed ID: 20225655
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of hepatitis C: therapeutic management].
    Bourliere M.
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 2):S166-71. PubMed ID: 18482813
    [No Abstract] [Full Text] [Related]

  • 16. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP, Younossi ZM.
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An adult case with onset of celiac disease during chronic hepatitis C antiviral treatment.
    Ioniţă-Radu F, Bucurică S, Costache R, Nuţă P, Stanciu S.
    Rom J Intern Med; 2010 May; 48(1):105-8. PubMed ID: 21180248
    [Abstract] [Full Text] [Related]

  • 20. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I, Papatheodoridis G, Pectasides D.
    J Viral Hepat; 2014 May; 21(9):624-32. PubMed ID: 24224747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.